Edition:
United Kingdom

Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

8.39USD
4:26pm GMT
Change (% chg)

$-0.06 (-0.71%)
Prev Close
$8.45
Open
$8.45
Day's High
$8.60
Day's Low
$8.30
Volume
10,795
Avg. Vol
65,106
52-wk High
$21.30
52-wk Low
$3.13

Chart for

About

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $24.57
Shares Outstanding(Mil.): 4.31
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Catalyst biosciences Q3 loss per share $1.34

* Catalyst Biosciences reports third quarter 2017 operating & financial results and provides corporate update

02 Nov 2017

BRIEF-Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration

* Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration to develop intravitreal anti-complement factor 3 (c3) products for the treatment of dry amd and other retinal diseases

24 Oct 2017

BRIEF-Catalyst Biosciences Inc - ‍companies plan to have interim, top-line results by end of 2017

* Catalyst Biosciences granted FDA orphan drug designation for subcutaneous recombinant human Factor IX variant for treatment of hemophilia B

26 Sep 2017

BRIEF-Catalyst Biosciences announces successful completion of first subcutaneous dosing cohort in ongoing hemophilia B clinical trial

* Catalyst Biosciences announces successful completion of first subcutaneous dosing cohort in ongoing hemophilia B clinical trial

25 Sep 2017

BRIEF-Catalyst Biosciences Inc announces issuance of Asia patents covering Factor IX Hemophilia Program

* Catalyst Biosciences Inc - announces issuance of Asia patents covering factor IX Hemophilia Program Source text for Eikon: Further company coverage:

11 Sep 2017

BRIEF-Catalyst Biosciences' reports positive data on hemophilia B drug

* Catalyst Biosciences announces positive factor ix clinical data

06 Sep 2017

BRIEF-Catalyst Biosciences posts Q2 loss of $2.53 per share

* Catalyst biosciences reports second quarter 2017 financial results and provides subcutaneous (sq) hemophilia program update

03 Aug 2017

BRIEF-Financial milestone achieved in Catalyst's subcutaneous factor IX program

* Financial milestone achieved in Catalyst's subcutaneous factor IX program

06 Jul 2017

BRIEF-Catalyst Biosciences' Factor IX granted orphan drug designation in Europe

* Catalyst Biosciences' Factor IX granted orphan drug designation in Europe

28 Jun 2017

BRIEF-Catalyst Biosciences announces achievement of stable normal factor IX blood levels in a preclinical subcutaneous dosing model

* Catalyst Biosciences announces achievement of stable normal factor IX blood levels in a preclinical subcutaneous dosing model Source text for Eikon: Further company coverage:

26 Jun 2017

Earnings vs. Estimates